Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.54 |
| ▸ | FPR2 | P25090 | 4/20 | 0.53 |
| ▸ | FPR1 | P21462 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680780 | 0.87 | F10 (0.59) | F10FPR2FPR1 | |
| SCHEMBL6853164 | 0.87 | F10 (0.53) | F10FPR2FPR1 | |
| SCHEMBL6853111 | 0.83 | F10 (0.52) | F10FPR2FPR1 | |
| SCHEMBL6859980 | 0.81 | F10 (0.53) | F10FPR2FPR1 | |
| SCHEMBL4680601 | 0.78 | F10 (0.79) | F10FPR2FPR1 | |
| SCHEMBL4679648 | 0.77 | F10 (0.71) | F10FPR2FPR1 | |
| SCHEMBL6859806 | 0.75 | F10 (0.43) | F10 | |
| SCHEMBL4680188 | 0.75 | F10 (0.69) | F10FPR2FPR1 | |
| SCHEMBL6853311 | 0.75 | F10 (0.42) | F10 | |
| SCHEMBL4683366 | 0.75 | F10 (0.69) | F10FPR2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790845-B2 | HAVING AN ATTACHED NON-AROMATIC HETEROCYCLIC RING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-14 | — | — | US | claimed |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | claimed |
| US-6790845-B2 | HAVING AN ATTACHED NON-AROMATIC HETEROCYCLIC RING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | TFPI, F11, F12 | F10 9/4885FPR2 2188/4885FPR1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.